Basel, Switzerland – March, 2022
SpiroChem AG, a Swiss Discovery Chemistry CRO with pioneering expertise in the design of sp3-rich molecules and their application to generate better drug candidates and accelerate discovery research, appointed Dr. Sven Wagner, as Chief Business Officer.
Dr. Wagner brings over 20 years of experience in the biopharmaceutical and CRO/CMO industries, in different leadership functions such as business development, corporate strategy, alliance and innovation management. His role within SpiroChem will be to guide the strong growth of the company and oversee the consistent and continued success of SpiroChem’s medicinal chemistry discovery services.
Prior to joining SpiroChem, Dr. Wagner worked at Eurofins Advinus, Wildflower Biopharma, GVK Bio, deCODE genetics, ChemBridge, Merck KGaA and Peninsula Laboratories.
Originally from Germany, Dr. Wagner holds a M.S. in organic chemistry from the University of Leipzig, and obtained a Ph.D. in pharmaceutical sciences from the German Cancer Research Center (DKFZ) and the University of Heidelberg.
SpiroChem AG is a privately-held, best-in-class Contract Research Organization (CRO) headquartered in Basel, Switzerland. Originally focused on the application of elite synthetic chemistry skills to unlock synthesis access and remove bottlenecks in discovery, SpiroChem is now covering the entire discovery chemistry value chain, from proprietary screening libraries (diverse high-sp3 FBLs and scaffolds for DELs) to design (CADD) and synthesis (medicinal chemistry and medicinal chemistry-enabling platform) of bioactive molecules, all the way to early CMC (route scouting). SpiroChem clients are located worldwide and include VC-backed biotech companies, large pharma organizations and university spin-offs looking for a partner providing knowledge and speed to their projects.
SpiroChem has over 75 employees in Switzerland and is actively recruiting to further expand due to the high demand for its services and solutions. Our elite team of synthetic and medicinal chemists was trained in world leading institutions and combines years of industrial experiences in pharma, biotechs and CRO companies. With a higher-than-average PhD-trained composition, our team has demonstrated since inception in 2011 that “Chemistry is the solution, not the problem”. We delivered on highly complex discovery projects where our chemical capabilities were essential for the success. Our challenge-minded attitude means that we do not shy away from complexity, even when natural products, carbohydrates, lipids and nucleosides are involved. Our unique set of chemical expertise is a strong component of our offering and supports with proprietary compounds and tools all downstream medicinal chemistry efforts in a seamless manner.